GT Biopharma, Inc. financial data

Symbol
GTBP on Nasdaq
Industry
Pharmaceutical Preparations
Location
8000 Marina Blvd, Suite 100, Brisbane, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
OXIS INTERNATIONAL INC (to 7/25/2017)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 245 % -38.6%
Debt-to-equity 68.8 % +49.2%
Return On Assets -91.9 % -18.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.23M shares -94.5%
Common Stock, Shares, Outstanding 2.23M shares -94.5%
Entity Public Float 11.5M USD -87.2%
Common Stock, Value, Issued 2K USD -95.1%
Weighted Average Number of Shares Outstanding, Basic 1.71M shares +27.8%
Weighted Average Number of Shares Outstanding, Diluted 1.71M shares +27.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.28M USD -43.4%
Operating Income (Loss) -13.3M USD +33.9%
Nonoperating Income (Expense) 1.93M USD -64.2%
Net Income (Loss) Attributable to Parent -11.4M USD +22.7%
Earnings Per Share, Basic -7.75 USD/shares +63.3%
Earnings Per Share, Diluted -7.75 USD/shares -45.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.25M USD +234%
Cash, Cash Equivalents, and Short-term Investments 9.2M USD -48.9%
Assets, Current 9.27M USD -48.6%
Operating Lease, Right-of-Use Asset 27K USD -80.7%
Assets 9.27M USD -48.9%
Accounts Payable, Current 1.72M USD -51%
Accrued Liabilities, Current 1.77M USD +44.4%
Liabilities, Current 3.76M USD -22.4%
Operating Lease, Liability, Noncurrent 31K USD -78.9%
Liabilities 4.6M USD -34.6%
Retained Earnings (Accumulated Deficit) -688M USD -1.68%
Stockholders' Equity Attributable to Parent 5.51M USD -53.2%
Liabilities and Equity 9.27M USD -48.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.16M USD -43.3%
Net Cash Provided by (Used in) Financing Activities 6.27M USD
Net Cash Provided by (Used in) Investing Activities 3.53K USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 2.23M shares -94.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 871K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.25M USD +234%
Deferred Tax Assets, Valuation Allowance 110M USD -2.92%
Deferred Tax Assets, Gross 110M USD -2.92%
Operating Lease, Liability 30K USD -80.9%
Lessee, Operating Lease, Liability, to be Paid 30K USD -79.6%
Operating Lease, Liability, Current 30K USD -74.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 91K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 60M USD +49080%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1K USD
Preferred Stock, Shares Issued 96.2K shares
Preferred Stock, Shares Authorized 15M shares 0%
Operating Lease, Payments 19.7M USD
Additional Paid in Capital 694M USD +0.75%
Preferred Stock, Shares Outstanding 96.2K shares
Interest Expense 212K USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%